Publications by authors named "Anne-Laure Remond"
Article Synopsis
- Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 are important for metastatic cancer treatment but can cause immune-related adverse events (irAEs), particularly affecting the eyes.
- This study assessed patients from June 2014 to March 2018 who experienced moderate-to-severe ocular irAEs after anti-PD-(L)1 treatment, revealing a prevalence of 0.4% among 745 patients.
- Results showed various ocular complications, with 62.5% of patients also having other irAEs; timely ophthalmologist consultation is recommended for patients experiencing eye issues during treatment.
Driving and vision disorders. Optimal vision is mandatory for safe driving. Many either acute or chronic ophthalmological conditions may unconsciously alter the driver's vision.
View Article and Find Full Text PDF